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3-(Thiophen-2-yl)-4,5-dihydro-1H-pyrazole-1-carboximidamides were efficiently prepared 
through a cyclocondensation of thiophenylchalcones with aminoguanidine hydrochloride under 
ultrasonic conditions in the presence of KOH and ethanol as a green solvent in short reaction times 
(15-35 min) and good yields (62-95%). All compounds produced were evaluated against the human 
Jurkat and RS4;11 acute lymphoblastic leukemia cell lines of T- and B-cell origin, respectively, 
and the K562 myelogenous leukemia cell line. Six compounds presented half maximal inhibitory 
concentration (IC50) values around 15 µmol L-1 and five compounds presented IC50 values around 
40 µmol L-1 for at least one of the three cell lines analyzed. One compound was not significantly 
cytotoxic, presenting IC50 value > 100 µmol L-1.
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Introduction
Amidine functional group has proven to be an important 
fragment in compounds with recognized bioactivities. 
In this sense, several amidines have been prepared and 
their antifungal,1 antiprotozoal,2 antibacterial,3 anti-HIV,4 
antithrombotic,5 and antidegenerative6 potentials have been 
evaluated. Pentamidine is clinically used for treatment of 
pneumonia and first stage human African tripanosomiasis.7 
That drug is on the WHO’s List of Essential Medicines for 
the basic health system.8 Moreover, amidine containing 
molecules have been pointed as proeminent prototypes 
in the search for new anticancer agents.9 In addition, 
thiophene-2-carboximidamides have shown potent and 
selective inhibitory activities of nitric oxide synthases for 
the treatment of human melanoma.10
In the same context, pyrazoles are recognized as a 
fundamental class of heterocyclic compounds because 
of their well-established applicability in several areas 
as agrochemicals, functional materials and medicines.11 
Dihydro-1H-pyrazole derivatives have been reported as 
antiproliferative agents12 and inhibitors of vascular endothelium 
growth factors,13 mitotic kinesin spindle protein (KSP),14 
and multidrug resistance protein 1 (MDR1).15 Pyrazoline 
derivatives have shown high selectivity against leukemia cell 
lines (the concentration for 50% of maximal inhibition of 
cell proliferation, GI50 = 0.69-3.35 µmol L-1) in comparison 
with eight other tumor cell lines.16
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Taking into account the valuable pharmacological 
properties of pyrazoline and amidine scaffolds, we 
envisioned that hybrid molecules could be active against 
leukemia cells. Analogous 4,5-dihydro-1H-pyrazole-
1-carboximidamides have been already prepared by 
the cyclocondensation of α,β-unsaturated ketones with 
aminoguanidine free base under conventional17 and 
sonochemical18 conditions. However, to the best of 
our knowledge there are not reported studies about the 
antileukemic potency of these hybrid molecules.
Thus, in our continuous efforts to develop sonochemically 
promoted reactions in environmentally benign solvents19 
and synthetic methodologies for preparation of heterocyclic 
compounds20 selected on the basis of their biological 
activity,21 we describe herein a rapid and efficient synthetic 
method for the preparation of 3-(thiophen-2-yl)-4,5-
dihydro-1H-pyrazole-1-carboximidamide hydrochlorides 
under ultrasonic conditions. In addition, all compounds 
synthetized were evaluated against the human Jurkat and 
RS4;11 acute lymphoblastic leukemia cell lines of T- and 





3-Aryl-1-(thiophen-2-yl)prop-2-en-1-ones 1a-l were 
prepared by us following reported procedures.22 All the 
chemicals were used without purification as purchased 
from commercial suppliers. The sonicated reactions were 
carried out with a microtip probe connected to a 500 W 
Sonics Vibracell ultrasonic processor operating at 20 kHz 
at 20% of the maximum power output. Reaction progresses 
were monitored by gas chromatography (GC). Melting 
point values were determined in open capillary on an 
Instrutherm DF-3600 II apparatus and are uncorrected. 
Infrared spectra (IR) were acquired on a JASCO-4100 
spectrophotometer as KBr pellets. 1H and 13C nuclear 
magnetic resonance (NMR) spectra were acquired on a 
Bruker DPX400 instrument (400 MHz for 1H and 101 MHz 
for 13C) in 5 mm sample tubes at 298 K in dimethyl 
sulfoxide (DMSO-d6) using tetramethylsilane (TMS) as 
internal reference standard. High resolution mass spectra 
were recorded on a Bruker microTof (Q-TOF) mass 
spectrometer in electrospray ionization (ESI) mode.
General procedure for the ultrasound-promoted synthesis 
of 5-aryl-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazole-1-
carboximidamides (2a-l)
To a 50 mL vial containing a solution of 3-aryl-1-
(thiophen-2-yl)prop-2-en-1-ones 1a-l (1 mmol) in ethanol 
(15 mL), the aminoguanidine hydrochloride (0.22 g, 
2 mmol) and KOH (0.11 g, 2 mmol) were added. The 
reaction mixture was sonicated for the time indicated in 
Table 1 and the reaction temperature reached 55-60 ºC 
after 10 minutes. The resulting solution was cooled to room 
temperature and acidified using 10% HCl (10-15 mL). 
The salts were extracted with chloroform (3 × 20 mL) 
and the combined organic layer was dried over anhydrous 
magnesium sulfate. Removal of solvent under vacuum 
afforded a crude material. The pure products 2a-l were 
obtained as amorphous solids with yields of 62-95% 




Yellowish solid; mp 
266-268 ºC;  IR (KBr) 
ν / cm-1 3337, 3115, 1609, 
1430; 1H NMR (400 MHz, 
DMSO-d6) d 7.97 (bs, 4H, 
C(NH2)2) ,  7.86 (d,  1H, 
J 5.0 Hz, T-H*), 7.57 (d, 
1H, J 3.6 Hz, T-H), 7.39 (d, 2H, J 7.6 Hz, Ph-H), 7.35-7.32 
(m, 1H, Ph-H), 7.25 (d, 2H, J 7.4 Hz, Ph-H), 7.20-7.17 (m, 
1H, T-H), 6.02 (dd, 1H, J 2.4, 11.0 Hz, Hx†), 4.11 (dd, 1H, 
J 11.2, 17.8 Hz, Hm†), 3.36 (dd, 1H, J 2.7, 17.8 Hz, Ha†); 
13C NMR (101 MHz, DMSO-d6) d 153.2, 153.0, 139.6, 
132.7, 132.0, 131.3, 129.0, 128.2, 125.3, 60.4, 44.4; HRMS 
m/z, [M + H]+ calcd. for C14H15N4S: 271.1017; found: 




Yellowish solid; mp 287-
288 ºC; IR (KBr) ν / cm-1 
3255, 3190, 3103, 1618, 
1423 ,  1243 ;  1H  NMR 
(400 MHz, DMSO-d6) d 7.85 
(bs, 4H, C(NH2)2), 7.82 (dd, 
1H, J 0.9, 5.0 Hz, T-H), 7.54 
(dd, 1H, J 0.8, 3.6 Hz, T-H), 7.34 (m, 1H, Ph-H), 7.16 
(dd, 1H, J 3.8, 5.0 Hz, T-H), 7.11 (d, 1H, J 8.2 Hz, Ph-H), 
6.97-6.89 (m, 2H, Ph-H), 5.87 (dd, 1H, J 3.2, 11.1 Hz, Hx), 
4.04 (dd, 1H, J 11.1, 17.7 Hz, Hm), 3.83 (s, 3H, Ph−OCH3), 
3.24 (dd, 1H, J 3.2, 17.7 Hz, Ha); 13C NMR (101 MHz, 
DMSO-d6) d 156.2, 153.8, 152.9, 132.8, 131.8, 131.1, 
129.6, 128.2, 126.3, 124.9, 120.3, 111.8, 57.2, 55.7, 43.3; 
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Yellowish solid; mp 
285-288 ºC;  IR (KBr) 
ν / cm-1 3290, 3117, 1603, 
1423; 1H NMR (400 MHz, 
DMSO-d6) d 8.03 (bs, 4H, 
C(NH2)2) ,  7.86 (d,  1H, 
J 4.9 Hz, T-H), 7.57 (d, 
1H, J 3.4 Hz, T-H), 7.55 
(d, 1H, J 8.1 Hz, Ph-H), 7.48 (m, 1H, Ph-H), 7.38 (t, 
1H, J 7.9 Hz, Ph-H), 7.22-7.18 (m, 2H, T-H and Ph-H), 
6.04 (dd, 1H, J 2.8, 11.2 Hz, Hx), 4.11 (dd, 1H, J 11.2, 
17.9 Hz, Hm), 3.42 (dd, 1H, J 2.9, 17.9 Hz, Ha); 13C NMR 
(101 MHz, DMSO-d6) d 153.2, 153.1, 135.2, 133.4, 132.6, 
132.3, 132.0, 131.3, 129.8, 128.1, 127.6, 126.7, 58.6, 43.2; 




Yellowish solid; mp 
288-291 ºC; IR (KBr) 
ν / cm-1 3363, 3284, 
3204, 3103, 1611, 
1524, 1423, 1344, 847; 
1H NMR (400 MHz, 
DMSO-d6) d 8.22 (ddd, 
1H, J 0.9, 2.2, 8.2 Hz, Ph-H), 8.10 (t, 1H, J 1.9 Hz, 
Ph-H), 7.97 (s, 4H, C(NH2)2), 7.87 (dd, 1H, J 1.1, 5.0 Hz, 
T-H), 7.74 (t, 1H, J 8.0 Hz, Ph-H), 7.65 (d, 1H, J 7.9 Hz, 
Ph-H), 7.55 (dd, 1H, J 1.1, 3.7 Hz, T-H), 7.20 (dd, 1H, 
J 3.7, 5.0 Hz, T-H), 6.07 (dd, 1H, J 3.2, 11.3 Hz, Hx), 
4.16 (dd, 1H, J 11.4, 18.0 Hz, Hm), 3.48 (dd, 1H, J 3.2, 
18.0, Ha); 13C NMR (101 MHz, DMSO-d6) d 153.2, 152.8, 
148.0, 141.5, 132.5, 132.2, 132.0, 131.5, 130.9, 128.2, 
123.2, 120.7, 59.6, 44.3; HRMS m/z, [M + H]+ calcd. for 




mp 278-280 ºC; IR 
(KBr) ν / cm-1 3255, 
3096, 1611, 1430; 
1H NMR (400 MHz, 
DMSO-d6) d 7.91 (bs, 
4H, C(NH2)2), 7.84 (d, 
1H, J 5.0 Hz, T-H), 7.56 (d, 1H, J 3.6 Hz, T-H), 7.21-7.17 
(m, 3H, T-H and Ph-H), 7.13 (d, 2H, J 8.1 Hz, Ph-H), 
5.92 (dd, 1H, J 3.0, 11.1 Hz, Hx), 4.07 (dd, 1H, J 11.2, 
17.9 Hz, Hm), 3.33 (dd, 1H, J 3.0, 17.7 Hz, Ha), 2.28 (s, 
3H, Ph-CH3); 13C NMR (101 MHz, DMSO-d6) d 153.1, 
153.0, 137.6, 136.6, 132.8, 131.9, 131.2, 129.5, 128.2, 
125.3, 60.2, 44.3, 20.6; HRMS m/z, [M + H]+ calcd. for 




mp 295-298 ºC; IR 
(KBr) ν / cm-1 3370, 
3290, 3068, 1603, 
1423, 1315-1113, 839; 
1H NMR (400 MHz, 
DMSO-d6) d 8.14 (bs, 
4H, C(NH2)2), 7.88 (d, 1H, J 4.7 Hz, T-H), 7.79 (d, 2H, 
J 8.2 Hz, Ph-H), 7.60 (d, 1H, J 3.1 Hz, T-H), 7.52 (d, 2H, 
J 8.1 Hz, Ph-H), 7.21-7.19 (m, 1H, T-H), 6.27 (dd, 1H, J 2.4, 
11.0 Hz, Hx), 4.19 (dd, 1H, J 11.3, 17.8 Hz, Hm), 3.45 (dd, 
1H, J 2.8, 17.9 Hz, Ha); 13C NMR (101 MHz, DMSO-d6) 
d 153.1, 153.0, 143.9 (q, J 1.3 Hz), 132.5, 132.0, 131.3, 
128.7 (q, J 32.0 Hz), 128.1, 126.3, 125.8 (q, J 3.8 Hz), 123.9 
(q, J 272.1 Hz), 60.0, 44.2; HRMS m/z, [M + H]+ calcd. for 




m p  2 9 6 - 2 9 9 ° C ; 
IR (KBr) ν / cm-1 
3334-3132, 1611, 
1438, 1243, 839; 
1H NMR (400 MHz, 
DMSO-d6) d 7.85 
(dd, 1H, J 1.0, 5.0 Hz, T-H), 7.76 (bs, 4H, C(NH2)2), 7.56 
(dd, 1H, J 1.1, 3.7 Hz, T-H), 7.19 (dd, 1H, J 3.7, 5.0 Hz, 
T-H), 7.16-7.09 (m, 2H, Ph-H), 7.01-6.89 (m, 2H, Ph-H), 
5.79 (dd, 1H, J 2.4, 11.0 Hz, Hx), 4.05 (dd, 1H, J 11.1, 
17.8 Hz, Hm), 3.73 (s, 3H, Ph-OCH3), 3.41-3.26 (m, 1H, 
Ha); 13C NMR (101 MHz, DMSO-d6) d 159.2, 153.3, 152.7, 
132.8, 132.0, 131.5, 131.3, 128.2, 126.7, 114.4, 60.0, 




Yellowish solid; mp 243-245 ºC; IR (KBr) ν / cm-1 
3348-3103, 1596, 1416, 1229, 832; 1H NMR (400 MHz, 
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DMSO-d6) d 7.93 (s, 
4H, C(NH2)2), 7.86 (dd, 
1H, J 1.1, 5.0 Hz, T-H), 
7.57 (dd, 1H, J 1.1, 
3.7 Hz, T-H), 7.33-
7.21 (m, 4H, Ph-H), 
7.19 (dd, 1H, J 3.7, 
5.0 Hz, T-H), 5.94 (dd, 1H, J 2.9, 11.2 Hz, Hx), 4.09 
(dd, 1H, J 11.2, 17.9 Hz, Hm), 3.53-3.27 (m, 1H, Ha); 
13C NMR (101 MHz, DMSO-d6) d 163.1, 160.6, 153.0 
(d, J 34.2 Hz), 135.8 (d, J 2.7 Hz), 132.7, 132.1, 131.4, 
128.2, 127.6 (d, J 8.3 Hz), 115.9 (d, J 21.7 Hz), 59.7, 44.4; 





mp 257-260 ºC; IR 
(KBr) ν / cm-1 3070, 
1 6 0 6 ,  1 4 2 5 ,  8 2 5 ; 
1H NMR (400 MHz, 
DMSO-d6) d 7.98 (bs, 
4H, C(NH2)2), 7.85 (d, 
1H, J 4.8 Hz, T-H), 7.56 (d, 1H, J 3.1 Hz, T-H), 7.47 
(d, 2H, J 8.2 Hz, Ph-H), 7.27 (d, 2H, J 8.3 Hz, Ph-H), 
7.20-7.18 (m, 1H, T-H), 6.01-5.99 (m, 1H, Hx), 4.10 
(dd, 1H, J 11.2, 17.8 Hz, Hm), 3.40-3.35 (m, 1H, Ha); 
13C NMR (101 MHz, DMSO-d6) d 153.2, 152.9, 138.5, 
132.9, 132.6, 132.1, 131.4, 129.0, 128.2, 127.4, 59.8, 44.3; 




Yellowish solid; mp 
265-266 ºC; IR (KBr) 
ν / cm-1 3269, 3190, 
3103, 1611, 1430; 
1H NMR (400 MHz, 
DMSO-d6) d 8.01 (bs, 
4H, C(NH2)2), 7.85 (d, 
1H, J 5.0 Hz, T-H), 7.60 (d, 2H, J 8.3 Hz, Ph-H), 7.56 (d, 
1H, J 3.6 Hz, T-H), 7.22 (d, 2H, J 8.4 Hz, Ph-H), 7.20-7.18 
(m, 1H, T-H), 6.03 (dd, 1H, J 2.6, 11.1 Hz, Hx), 4.11 (dd, 
1H, J 11.3, 17.8 Hz, Hm), 3.38 (dd, 1H, J 2.7, 17.8 Hz, Ha); 
13C NMR (101 MHz, DMSO-d6) d 153.0, 152.9, 138.8, 
132.5, 131.9, 131.8, 131.2, 128.1, 127.6, 121.3, 59.7, 44.1; 




Yellowish solid; mp 
290-293 ºC; IR (KBr) 
ν / cm-1 3334, 3175, 
3103, 1611, 1423, 825; 
1H NMR (400 MHz, 
DMSO-d6) d 8.00 (bs, 
4H, C(NH2)2), 7.85 (dd, 
1H, J 1.1, 5.0 Hz, T-H), 7.56 (dd, 1H, J 1.1, 3.7 Hz, T-H), 
7.55-7.53 (m, 1H, Ph-H), 7.48-7.47 (m, 1H, Ph-H), 7.38 (t, 
1H, J 7.9 Hz, Ph-H), 7.21-7.18 (m, 2H, T-H and Ph-H), 
6.02 (dd, 1H, J 3.1, 11.2 Hz, Hx), 4.10 (dd, 1H, J 11.3, 
17.9 Hz, Hm), 3.42 (dd, 1H, J 3.1, 17.9 Hz, Ha); 13C NMR 
(101 MHz, DMSO-d6) d 153.1, 152.9, 142.0, 132.5, 132.0, 
131.2, 131.2, 131.0, 128.4, 128.1, 124.1, 121.9, 59.6, 44.2; 





mp  287-291  ºC; 
IR (KBr) ν / cm-1 
3298, 3139, 2830, 
1 6 1 8 ,  1 4 3 0 ; 
1H NMR (400 MHz, 
DMSO-d6) d 7.84 
(dd, 1H, J 1.0, 5.0 Hz, T-H), 7.80 (bs, 4H, C(NH2)2), 7.56 
(dd, 1H, J 1.0, 3.6 Hz, T-H), 7.19 (dd, 1H, J 3.7, 5.0 Hz, 
T-H), 6.96 (d, 1H, J 8.3 Hz, Ph-H), 6.92 (d, 1H, J 1.9 Hz, 
Ph-H), 6.67 (dd, 1H, J 1.9, 8.3 Hz, Ph-H), 5.78 (dd, 1H, 
J 2.9, 11.1 Hz, Hx), 4.05 (dd, 1H, J 11.1, 17.8 Hz, Hm), 3.75 
(s, 3H, Ph-OCH3), 3.73 (s, 3H, Ph-OCH3), 3.40-3.36 (m, 
1H, Ha); 13C NMR (101 MHz, DMSO-d6) d 153.2, 152.8, 
148.9, 148.7, 132.8, 131.8, 131.8, 131.8, 131.1, 128.2, 
116.9, 112.3, 110.1, 60.3, 55.6, 44.4; HRMS m/z, [M + H]+ 
calcd. for C16H19N4O2S: 331.1229; found: 331.1252.
In vitro citotoxicity assay (MTT assay)
In vitro cytotoxicity assay was carried out on three 
different human leukemia cell lines: K562, erythroleukemia 
cells bearing the t(9;22)(q34;q11)-derived BCR/ABL1 
fusion gene; Jurkat, T-cells acute lymphoblastic leukemia 
(ALL) cells; and RS4;11, B-cell precursor ALL cells 
bearing the t(4;11)(q21;q23)-derived KMT2A/AFF1 fusion 
gene. The cells were maintained in RPMI-1640 (Cultilab) 
supplemented with 10% fetal bovine serum (FBS; Cultilab) 
and penicillin/streptomycin, at 37 °C and 5% CO2. For 
the cytotoxicity assay, compounds 2a-l were dissolved in 
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DMSO in order to obtain a stock solution of 20 mmol L-1. 
Further dilutions were made in complete culture medium 
immediately before use. K562 and Jurkat cells were seeded 
at 3 × 104 cells per well while RS4;11 cells were seeded at 
4 × 104 cells per well in a 96-well plate . After that, 20 µL 
of 10-fold serial dilutions of compounds 2a-l or vehicle 
(DMSO at a final concentration of 0.5%) were added to 
each well, in triplicate, at final concentrations of 0.1, 1.0, 
10 and 100 µmol L-1. Culture plates were kept at 37 °C 
and 5% CO2 for 48 h, then, cell viability was measured by 
adding 20 µL of the MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) reagent (Sigma-Aldrich) 
at 5 mg mL-1. After 4 h, the precipitated formazan crystals 
were dissolved by the addition of 100 µL of an acid sodium 
dodecyl sulfate solution (10% SDS, 0.01 mol L-1 HCl). 
Following overnight incubation, absorbance was measured 
at 570 nm for the MTT reaction and 620 nm as reference on 
scanning. Viability was calculated as a percentage of viable 
cells at different test concentrations relative to the control 
(vehicle-treated) cells. The concentration of compounds 2a-l 
that resulted in 50% inhibition of cell growth was calculated 
as the half maximal inhibitory concentration (IC50) by 
constructing a dose-response curve using GraphPad Prism 




(2a-l) were synthesized in good yields by the ultrasound-
assisted cyclocondensation reaction between compounds 
1a-l ,  prepared as described in literature,22 and 
aminoguanidine hydrochloride in the presence of KOH 
using ethanol as a green solvent (Table 1). The time 
required for the completion of the reaction depends on the 
nature of the groups attached to the benzene ring and it was 
determined by monitoring de consumption of the carbonyl 
compound by gas chromatography (GC) in intervals of 
5 minutes. After the total consumption of the starting 
materials 1a-l the reaction solution was acidified with HCl 
in order to obtain the salts of the products. As showed in 
Table 1, the reaction tolerate electron-withdrawing and 
electron-donating groups. In general, substrates that contain 
electron-withdrawing substituents such as 3-NO2 (Table 1, 
entry 4) and 4-CF3 (Table 1, entry 6) gave products in 
shorter reaction times but in lower yields.
The structure of the carboximidamides were confirmed 
by IR, 1H and 13C NMR and HRMS. The IR spectra showed 
Table 1. Cyclocondensation reactions between 1a-l and aminoguanidine hydrochloride in the presence of KOH for the preparation of carboximidamides 2a-l
 
entry Product R1 R2 R3 R4 timea / min Yieldb / %
1 2a H H H H 20 88
2 2b OMe H H H 25 80
3 2c Br H H H 30 70
4 2d H NO2 H H 15 65
5 2e H H Me H 35 80
6 2f H H CF3 H 15 62
7 2g H H OMe H 25 86
8 2h H H F H 30 73
9 2i H H Cl H 30 71
10 2j H H Br H 30 75
11 2k Cl H Cl H 30 66
12 2l H OMe OMe H 25 83
aSonication time; byields of the isolated compounds.
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sets of absorption bands in accordance with the proposed 
structures. In the 1H NMR spectra of the compounds, 
the characteristic signals of the AMX coupling system 
between pyrazolyl ring hydrogens, Ha, Hm and Hx, were 
observed as sets of three doublets of doublets in the d 3.48-
3.24, 4.19-4.04, and 6.27-5.78 ppm regions, respectively. 
Besides, the formation of the salts was confirmed by the 
presence of broad singlets in the range of d 8.14-7.76 ppm 
due to the presence of four equivalent hydrogens attached 
to nitrogens atoms in the carboximidamidyl moieties. The 
analysis of the 13C NMR and HRMS spectra also confirmed 
the structure of the products.
Although the mechanism of the cyclocondensation 
reaction between aminoguanidine and α,β-unsaturated 
ketones was not yet experimentally established, the 
literature shows a possible explanation based on the hard 
and soft acids and bases (HSAB) concept and quantum 
chemical studies on the aminoguanidine.17,23 Accordingly, 
a proposed mechanism is shown in Figure 1. Firstly, KOH 
neutralizes the aminoguanidine salt to give aminoguanidine 
in its free form, which can exist as two tautomers. Thus 
Aza-Michael-type addition from the internal imine nitrogen 
to the β-position of 1 leads to adduct I. In the next step, an 
intramolecular nucleophilic attack of the primary amino 
nitrogen to the carbonyl leads to intermediates II, which 
is dehydrated to give the product III. Finally, the addition 
of HCl produces the salt 2.
In vitro evaluation of antileukemia activity
To gain insight on structure-activity relationship, twelve 
pyrazoline derivatives (2a-l) had their cytotoxic activity 
evaluated against three different human leukemia cell lines 
(Table 2). Compounds 2b, 2c, 2f, 2i, 2j and 2k showed the 
best cytotoxic activity, with IC50 value around 15 µmol L-1 
for at least one of the three leukemia cell lines analyzed. 
Compounds 2a, 2d, 2e, 2g and 2h showed intermediate 
cytotoxic activity, with IC50 around 40 µmol L-1. Finally, 
compound 2l did not present a significant cytotoxic activity, 
with IC50 value >100 µmol L-1.
The in vitro cytotoxic activity of pyrazolines is in the 
same range to that of several anti-leukemia drugs used in 
the clinic: 6-mercaptopurine (20.9 and 233.4 µmol L-1, 
median IC50 values for a panel of seven T-cell and 
fifteen B-cell precursor ALL cell lines, respectively), 
6-thioguanine (4 and 11.8 µmol L-1), dexamethasone (82.7 
and 0.19 µmol L-1), and methylprednisolone (38.6 and 
69.8 µmol L-1).24 In conclusion, the cytotoxic activity of 
most pyrazolines is comparable to that of drugs used in 
leukemia treatment.
Conclusions
Ultrasound irradiation was efficient to promote the 
cyclocondensation reaction between thiophenylchalcones 
Figure 1. Proposed mechanism for the cyclocondensation reaction between 3-aryl-1-(thiophen-2-yl)prop-2-en-1-ones and aminoguanidine hydrochloride 
in the presence of KOH.
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and aminoguanidine hydrochloride in the presence of KOH, 
furnishing a series of twelve 3-(thiophen-2-yl)-4,5-dihydro-
1H-pyrazole-1-carboximidamides in short reaction times 
(15-35 min) and good yields (62-95%). All compounds 
prepared were evaluated against the human Jurkat and 
RS4;11 acute lymphoblastic leukemia cell lines of T- and 
B-cell origin, respectively, and the K562 myelogenous 
leukemia cell line. Six compounds presented IC50 values 
around 15 µmol L-1 and five compounds presented IC50 
values around 40 µmol L-1 for at least one of the three 
cell lines analyzed. One compound was not significantly 
cytotoxic presenting IC50 value > 100 µmol L-1.
Supplementary Information
Supplementary information (1H NMR, 13C NMR and 
HRMS spectra and dose-response curves) is available free 
of charge at http://jbcs.sbq.org.br as a PDF file.
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